RESEARCH
From Mechanism to Clinical Evidence
LifeBiotic evaluates proprietary botanical formulations through randomized clinical trials, mechanism-of-action research, and laboratory models of cellular and immune function.
Research Programs
BOTANICAL FORMULA
LCS103
Bladder Cancer (NMIBC) Reccurence Prevention
ACTIVE
Phase 2 Randomized Controlled
Clinical Trial
LCS103 is being evaluated in an active randomized controlled Phase 2 trial at Rambam Health Care Campus as an adjunct to standard care for non-muscle invasive bladder cancer. The program follows a peer-reviewed 20-patient case series reporting a recurrence-reduction signal.
BOTANICAL FORMULA
LCS101
A Multi-Targeted Approach to Cancer Care During Oncology Treatment
PUBLISHED
Phase 2 Randomized, Double-Blind Clinical Trial
LCS101 has been evaluated in clinical and laboratory studies for oncology supportive care, including chemotherapy-related hematological parameters, treatment-related symptoms, quality of life, immune activity, and compatibility with chemotherapy and radiation models.
BOTANICAL FORMULA
LCS102
Effect of the Innate Immunity and Chemotherapy Compatibility
PUBLISHED
Mechanisem and ilaboratory immune cellular research
LCS102 has been evaluated in human blood samples and cancer-cell laboratory models. The study showed significant activation of neutrophils and NK cells, while LCS102 did not reduce the cytotoxic activity of tested chemotherapy agents in the cell models studied.
Global Research Collaborations
LifeBiotic research has been conducted with oncologists, scientists, and academic medical teams from leading hospitals, cancer centers, and research institutions.
Scientific Validation
The LifeBiotic evidence program includes peer-reviewed publications and presentations at scientific and medical forums.
